ArkBio’s New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA
SHANGHAI, June 16, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio")…
ZEISS CLARUS 700 Receives NMPA Approval in China
ZEISS Medical Technology expands retinal insights for ophthalmologists with ultra-widefield, high-resolution imaging…
